Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic AneuRx Endovascular AAA Graft Should Be Approved - FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

Medtronic's AneuRx minimally invasive endovascular graft for abdominal aortic aneurysm repair was successfully implanted in 98% of the 416 patients treated in the company's pivotal trial to support premarket approval, study investigators said.

You may also be interested in...



Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy

A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.

Medtronic MIRACLE Foreshadows Resynchronized Approach To CHF Therapy

A clear clinical benefit demonstrated by Medtronic's InSync atrial synchronous biventricular pacing system in treating congestive heart failure could give FDA the impetus to bring resynchronization therapy to panel review as early as June.

Boston Scientific's Vanguard AAA Graft Effective For High-Risk Patients

Preliminary data from a study of Boston Scientific's Vanguard aortic endograft for treatment of abdominal aortic aneurysms (AAA) show a 97.6% success rate in high-risk patients. The results reinforce a growing consensus among clinicians that the minimally invasive procedure is preferable to standard open surgery for this population.

Related Content

UsernamePublicRestriction

Register

MT011976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel